Logo-hpp
2022: Two-year Impact Factor: 4.4
Scopus Journal Metrics
CiteScore (2022): 5.3
SNIP(2022):1.389
SJR(2022): 0.78
Platinum
Open Access

Health Promot Perspect. 2019;9(3): 248-254. doi: 10.15171/hpp.2019.34
PMID: 31508346        PMCID: PMC6717926

Original Article

Profile of drug users in the residential treatment centers of Tehran, Iran

Hossein Akbari 1, Mohsen Roshanpajouh 1, Keramat Nourijelyani 1, Mohammad-Ali Mansournia 1, Afarin Rahimi-Movaghar 1 * ORCID, Kamran Yazdani 1

Cited by CrossRef: 21


1- Moghanibashi-Mansourieh A, Dida R, Alizadeh M, Kheftan P, Danaeifar M, Balouchi M, Barati Sedeh F. Case management aftercare service provision to homeless people who use drugs in Iran; a nine-month post-treatment follow-up. Social Work in Mental Health. 2022;20(4):483 [Crossref]
2- Khani Jeihooni A, Sorbi A, Afzali Harsini P, Taghinezhad A, Yari A. The application of theory of planned behavior in improving substance abuse prevention behaviors in male high school students. Curr Psychol. 2023;42(13):11355 [Crossref]
3- Stakehold ZXSY: Disorder Deficit Familial Asynchrony and Syndrome Z. JMCCR. 2023; [Crossref]
4- Baheshmat S, Gholami J, Amin-Esmaeili M, Shadloo B, Rahimi-Movaghar A. Spouse and Child Abuse Associated With Illicit Drug Use in Iran: A Systematic Review and Meta-Analysis. Trauma, Violence, & Abuse. 2022;23(5):1494 [Crossref]
5- Rafiemanesh H, Shadloo B, Amin-Esmaeili M, Rahimi Y, Gholami J, Rahimi-Movaghar A. Prevalence of Tuberculosis among People Who Use Drugs in Iran: A Systematic Review and Meta-analysis. Addict Health. 2023;15(3):219 [Crossref]
6- Barati M, Bashirian S, Mohammadi Y, Moeini B, Mousali A, Afshari M. An ecological approach to exploring factors affecting substance use relapse: a systematic review. J Public Health (Berl). 2023;31(1):135 [Crossref]
7- Moghanibashi-Mansourieh A, Puyan D, Radfar R, Jafarian M, Legl T, Mattsson R, Hornberg E, Atefi F, Neuretter I, de Witte C, Farnam R, Binazade M, Deilamizade A. Challenges and Prescriptions for Homeless Drug Users’ Social Reintegration; An Experience of Partnerships Between Iran and Europe NGOs. Journal of Drug Issues. 2024;54(1):134 [Crossref]
8- Jormand H, Bashirian S, Barati M, Babamiri M, Rezapur-Shahkolai F. The Development of a Measuring Instrument for Substance Abuse Media Literacy Scale in Students. 2021;20(4):609 [Crossref]
9- Kpelly E, Schauder S, Bohm M, Sounga D, Moukouta C. Profiles and health risks (STIs, HCV, HIV) of injecting drug users. Revue d'Épidémiologie et de Santé Publique. 2022;70(6):299 [Crossref]
10- Radfar N, Radfar S, Mohammadi F, Azimi A, Amirkafi A, Tehrani-Banihashemi A. Retention rate in methadone maintenance treatment and factors associated among referred patients from the compulsory residential centers compared to voluntary patients. Front Psychiatry. 2023;14 [Crossref]
11- Rafiemanesh H, Rahimi-Movaghar A, Shadloo B, Rostam-Abadi Y, Nedjat S, Yazdani K. Prevalence, pattern, and associated factors of alcohol use disorder among male treatment-seeking people with illicit drug use disorder in Tehran, Iran. Journal of Substance Use. 2023;28(2):211 [Crossref]
12- Rafiemanesh H, Rahimi-Movaghar A, Haghdoost A, Noroozi A, Gholami J, Vahdani B, Afshar A, Salehi M, Etemad K. Opium dependence and the potential impact of changes in treatment coverage level: A dynamic modeling study. Health Promot Perspect. 2021;11(2):240 [Crossref]
13- Hosseini J, Shojaeefar E, Pooladgar P, Aliakbari F, Ganji M, Hamdieh M, Kheradmand A, Fashami M. Prevalence of substance use among Iranian male adolescents: Systematic review and meta‐analysis. Health Science Reports. 2022;5(6) [Crossref]
14- Moradi G, Hajarizadeh B, Rahmani K, Mohamadi-Bolbanabad A, Darvishi S, Zareie B, Zavareh F, Sharafi H, Alavian S, Ramazani R, Eftekhar M, Radfar S, Piroozi B, Gouya M. Drug use and risk behaviour profile, and the prevalence of HIV, hepatitis C and hepatitis B among people with methamphetamine use in Iran. International Journal of Drug Policy. 2019;73:129 [Crossref]
15- Ghanbari H, Toozandehjani H, Nejat H. Comparison of the Effectiveness of Acceptance and Commitment Therapy and Quality of Life Improvement Training on Distress Tolerance and Self-Destructive Behaviors in Substance Abusers. Int J Basic Sci Med. 2020;5(1):28 [Crossref]
16- Paknahad S, Akhgari M, Ghadipasha M. An alarming rise in the prevalence of deaths with methamphetamine involved in Tehran, Iran 2011-2018. Forensic Sci Med Pathol. 2021;17(2):208 [Crossref]
17- Rostam-Abadi Y, Rafiemanesh H, Gholami J, Shadloo B, Amin-Esmaeili M, Rahimi-Movaghar A. Hepatitis B virus infection among people who use drugs in Iran: a systematic review, meta-analysis, and trend analysis. Harm Reduct J. 2020;17(1) [Crossref]
18- Shadloo B, Baheshmat S, Rostam-Abadi Y, Shakeri A, Gholami J, Rahimi-Movaghar A. Comparison of self-reported substance use with biological testing among treatment-seeking patients with opioid use disorder. Journal of Substance Abuse Treatment. 2022;134:108555 [Crossref]
19- Ezati E, Baghcheghi N, Araban M, Karimy M, Koohestani H, Zabeti A, Hosseinzadeh H. Assessing drug use relapse rate and its associated factors among Iranian users. Journal of Substance Use. 2023;28(6):945 [Crossref]
20- Rostam-Abadi Y, Gholami J, Noroozi A, Ansari M, Baheshmat S, Hamzehzadeh M, Ghadirzadeh M, Vahdani B, Ekhtiari H, Mojtabai R, Rahimi-Movaghar A. Public health risks associated with methadone in Iran: A systematic review and meta-analysis. International Journal of Drug Policy. 2022;100:103529 [Crossref]

Indexing and Abstracting

2-year Impact Factor: 4.4

  


     Linked in Profile

   Academia Profile

Officially associated with The Iranian Health Education & Promotion Association  

Publication Advantages

Free of charge publication

Open access 

Fast and constructive peer review

Easy and fast online submission